KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Raw Materials (2016)

AbbVie (ABBV) has disclosed Raw Materials for 5 consecutive years, with $132.0 million as the latest value for Q2 2016.

  • Quarterly Raw Materials rose 4.76% to $132.0 million in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $132.0 million through Jun 2016, up 4.76% year-over-year, with the annual reading at $169.0 million for FY2015, 9.74% up from the prior year.
  • Raw Materials for Q2 2016 was $132.0 million at AbbVie, down from $155.0 million in the prior quarter.
  • The five-year high for Raw Materials was $261.0 million in Q4 2013, with the low at $126.0 million in Q2 2015.
  • Average Raw Materials over 5 years is $188.2 million, with a median of $163.0 million recorded in 2015.
  • Peak annual rise in Raw Materials hit 9.74% in 2015, while the deepest fall reached 45.02% in 2015.
  • Over 5 years, Raw Materials stood at $258.0 million in 2012, then increased by 1.16% to $261.0 million in 2013, then plummeted by 41.0% to $154.0 million in 2014, then grew by 9.74% to $169.0 million in 2015, then decreased by 21.89% to $132.0 million in 2016.
  • According to Business Quant data, Raw Materials over the past three periods came in at $132.0 million, $155.0 million, and $169.0 million for Q2 2016, Q1 2016, and Q4 2015 respectively.